Skip to main content
Fig. 1 | BMC Psychiatry

Fig. 1

From: Long-term mood/antidepressant effects of quetiapine extended-release formulation: an open-label, non-controlled extension study in Japanese patients with bipolar depression

Fig. 1

Study design. Values in boxes represent the dose of quetiapine XR in mg. *Patients were allocated to the quetiapine XR 300 mg group, the quetiapine XR 150 mg group, or the placebo group during the double-blind phase. **The dose was increased from 150 mg/day to 300 mg/day in patients who met the guideline for dose increase in week 14 or week 16. ***Dose adjustment from 300 mg/day to 150 mg/day, or vice versa, was allowed in accordance with the guideline

Back to article page